Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 3632

Next Previous
Drug Profile

AZD 3632

Alternative Names: AZD-3632

Latest Information Update: 29 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 04 Sep 2025 Preclinical trials in Haematological malignancies in USA (PO) prior to September 2025
  • 04 Sep 2025 AstraZeneca plans a phase I/II (MOMENTUM) trial for Haematological malignancies (Monotherapy, Combination therapy, Late stage disease, Second line therapy or greater) in the US, Canada, Germany, Italy, South Korea and UK (PO) in November 2025 (NCT07155226)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top